AngioSoma, Inc. (OTC: SOAN) Announces Agreement with Esther & Esther, Inc. to Maximize Sales of Its OTC Products with Existing Online Marketing Platform

Houston, TX, September 18, 2017 (PR.com) – AngioSoma, Inc. (OTC: SOAN) announces Agreement with Esther & Esther, Inc. to maximize sales of its OTC products with existing online marketing platform. Conjunctionally, the company’s subsidiary, Soma Nutraceuticals Inc., completed a licensing agreement with Kentucky-based East Kentucky Organic, Inc. to begin manufacturing of Soma Nutraceutical’s product line, Read more about AngioSoma, Inc. (OTC: SOAN) Announces Agreement with Esther & Esther, Inc. to Maximize Sales of Its OTC Products with Existing Online Marketing Platform[…]

AngioSoma, Inc. Starts SOMA Nutraceuticals, Inc.’s Operations

Houston, TX — (ReleaseWire) — 04/26/2017 — AngioSoma, Inc., (OTCMKTS:SOAN) recently filed its 10K for the period ending September 30, 2016 and its 10Q for the period ending December 31, 2016. AngioSoma, Inc.’s management would like to update its shareholders on recent progress within its 2017 business plan, including starting operations at its SOMA Nutraceuticals, Inc. Read more about AngioSoma, Inc. Starts SOMA Nutraceuticals, Inc.’s Operations[…]

November 2016 Shareholder Presentation

With so many changes at AngioSoma, Inc. over the last month, we wanted to update our September 2016 shareholder presentation to correctly reflect what AngioSoma, Inc. has been doing.  We have made the November 2016 AngioSoma, Inc. Shareholder Presentation available in both the PDF version and embedded here in its Microsoft PowerPoint version:   © 2016 by Read more about November 2016 Shareholder Presentation[…]

Uptick Newswire talks with Dr. David Summers

Released on October 25, 2016, Uptick Newswire’s Jasyn Blair interviewed Dr. Dr. David Summers, AngioSoma, Inc.’s Chairman Emeritus (entitled “Dr. David Summers, AngioSoma Inc., Talks Entering Joint Venture to Commercialize their Signature Product“.  We also make it available here: Other media outlets covering the interview… Investors Hangout (Front Page) iTunes iHeartRADIO Google Play Audio Boom! Read more about Uptick Newswire talks with Dr. David Summers[…]

Dr. Jackie R. See MD joins AngioSoma, Inc.’s Scientific Advisory Board

MONTGOMERY, TEXAS (Business Wire, October 20, 2016) – AngioSoma, Inc. (OTCQB SOAN) is in final negotiations with Dr. Jackie R. See, M.D., F.A.C.C. to join its Scientific Advisory Board.  Dr. See was instrumental in the original development of liposomal PGE-1 and is involved in new, and still experimental, uses of PGE-1 and stem cell treatment Read more about Dr. Jackie R. See MD joins AngioSoma, Inc.’s Scientific Advisory Board[…]

AngioSoma, Inc. Announces a Liprostin™ Focused Joint Venture

MONTGOMERY, Texas–(BUSINESS WIRE)–AngioSoma, Inc. (OTCQB:SOAN) announces a joint venture with La Jolla Capital Partners LLC (‘La Jolla’) focused on the funding and management of US Food and Drug Administration (‘FDA’) Liprostin™ Phase III trials, as well as the licensing of Liprostin™ worldwide thereafter. Liprostin™ is a liposomal encapsulated prostaglandin e1 (‘PGE1’) and is AngioSoma, Inc.’s Read more about AngioSoma, Inc. Announces a Liprostin™ Focused Joint Venture[…]

Shareholder Presentation, September 2016

Many of our current shareholders have many questions as to what AngioSoma, Inc. is doing, so we are making a shareholder presentation available (the PDF version available here) to all of our shareholders.  We intend to update this as we progress in our business plan.   © 2016 by AngioSoma, Inc., all rights reserved.

Angiosoma.com-product - ticker SOAN OTC

AngioSoma, Inc. enters discussions with Nutraceutical Intellectual Property Owners

Montgomery, Texas (September 21, 2016) – AngioSoma, Inc. (the ‘Company‘, ‘we‘, and ‘our‘), announces the formation of the Soma Nutraceuticals, Inc. subsidiary for the acquisition and marketing of proven nutraceutical products, as well as acquisition discussions with multiple proven nutraceutical intellectual properties. Our Chairman Emeritus “Doc” Summers owns some of the proven nutraceutical products we Read more about AngioSoma, Inc. enters discussions with Nutraceutical Intellectual Property Owners[…]

What type of news is provided by the company on Twitter?

As a publicly traded organization, AngioSoma, Inc. is an SEC reporting company, which requires the company to follow the mandates of Regulation Fair Disclosure (also known as “Regulation FD” or “Reg FD“).  Regulation FD requires public companies to “disclosure material information to all investors at the same time.” To that extent, AngioSoma, Inc. provides all Read more about What type of news is provided by the company on Twitter?[…]

AngioSoma’s Corporate Focus

July 14, 2016 09:00 AM Eastern Daylight Time MONTGOMERY, Texas–(BUSINESS WIRE)–AngioSoma, Inc. (OTCQB:SOAN), previously known as First Titan Corp. (the ‘Company‘, ‘we‘, and ‘our‘), changed our corporate name and focus to that of a clinical stage biopharmaceutical company introducing an exciting new treatment for one of the world’s most insidious and pervasive diseases, peripheral artery Read more about AngioSoma’s Corporate Focus[…]